ReviewCurrent opinion in infectious diseases2008
Development of protease inhibitors for protozoan infections.
Review in Current opinion in infectious diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 124 citations in OpenAlex.
- Review
- Oral infectivity through carnivorism in murine model ofFrontiers in cellular and infection microbiology · 2024Article
- Purification and characterization of cysteine protease of Sarcocystis fusiformis from infected Egyptian water buffaloes.Scientific reports · 2023Article
- In Vitro Antiprotozoal Activity ofBiology · 2023Article
- Variations in active proteases ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Article
- An Overview of NRF2-Activating Compounds Bearing α,β-Unsaturated Moiety and Their Antioxidant Effects.International journal of molecular sciences · 2022Review
- Effects of a Serine Protease Inhibitor N-Pharmaceutics · 2022Article
- Mechanisms Associated withLife (Basel, Switzerland) · 2021Review
- In vitro susceptibility of humanSaudi journal of biological sciences · 2021Article
- Article
- Antitrichomonal activity and docking analysis of thiazole derivatives as TvMP50 protease inhibitors.Parasitology research · 2021Article
- Repurposing Carvedilol as a Novel Inhibitor of theFrontiers in cellular and infection microbiology · 2021Article
- Article
- Structure-Based Virtual Screening and In Vitro Evaluation of NewInternational journal of molecular sciences · 2019Article
- High Throughput and Computational Repurposing for Neglected Diseases.Pharmaceutical research · 2018Review
- Discovery of Non-Peptidic Compounds against Chagas Disease Applying Pharmacophore Guided Molecular Modelling Approaches.Molecules (Basel, Switzerland) · 2018Article
- Naegleria fowleri after 50 years: is it a neglected pathogen?Journal of medical microbiology · 2016Article
- Development of a New Antileishmanial Aziridine-2,3-Dicarboxylate-Based Inhibitor with High Selectivity for Parasite Cysteine Proteases.Antimicrobial agents and chemotherapy · 2016Article
- Interactions between Trypanosoma cruzi Secreted Proteins and Host Cell Signaling Pathways.Frontiers in microbiology · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewTo highlight the promise of parasite proteases as targets for development of new antiparasitic chemotherapy. Proteolytic enzymes play key roles in the life cycle of protozoan parasites or the pathogenesis of diseases they produce. These roles include processing of host or parasite surface proteins for invasion of host cells, digestion of host proteins for nutrition, and inactivation of host immune defense mediators. RECENT
findingsDrug development for other markets has shown that proteases are druggable targets, and protease inhibitors are now licensed or in clinical development to treat hypertension, diabetes, thrombosis, osteoporosis, infectious diseases, and cancer. Several protease targets have been validated by genetic or chemical knockout in protozoan parasites. Many other parasite proteases appear promising as targets, but require more work for validation, or to identify viable drug leads. Because homologous proteases function as key enzymes in several parasites, targeting these proteases may allow development of a single compound, or a set of similar compounds, that target multiple diseases including malaria, trypanosomiasis, leishmaniasis, toxoplasmosis, cryptosporidiosis, and amebiasis. SUMMARY: Proteases have been validated as targets in a number of parasitic infections. Proteases are druggable targets as evidenced by effective antiprotease drugs for the treatment of many human diseases including hypertension and AIDS. Future drug development targeting parasite proteases will be aided by the strong foundation of biochemical, structural, and computational databases already published or available online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.